Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
$29.63+3.11%
报价 2026-11-06
市值
$2.13B
EV
$1.76B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -4.6%
$18.05$31.05
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ZYMEZymeworks Inc. | $2.13B | +3.1% | – | 98.4% | – | – | – | |
| AUPHAurinia Pharmaceuticals Inc. | $2.21B | +1.5% | – | 88.5% | 6.8x | 13.6x | – | |
| RXRXRecursion Pharmaceuticals, Inc. | $2.19B | +0.6% | -3.9% | -49.8% | – | – | – | |
| LKFTGalapagos N.V. Sponsored ADR | $2.19B | -0.3% | – | – | – | – | – | |
| BHVNBiohaven Ltd. | $2.19B | +4.2% | +55466.7% | 0% | – | – | – | |
| VERAVera Therapeutics, Inc. | $2.15B | -1.2% | – | 0% | – | – | – | |
| MRVIMaravai LifeSciences Holdings, Inc. | $2.13B | +7.7% | +14.0% | 34.6% | – | – | – | |
| FTREFortrea Holdings Inc. | $2.08B | +7.3% | -4.4% | 17.1% | – | 34.8x | 12.5x | |
| VIRVir Biotechnology, Inc. | $2.07B | +10.8% | +678.4% | 97.2% | – | – | – | |
| 同行中位数 | – | – | +14.0% | 17.1% | 6.8x | 24.2x | 12.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。